Volume 2, Issue 1 (2021)
- *Corresponding Author:
- Samim Akhtar
Department of Medical Oncology, Nepal Cancer Hospital, Nepal.
Tel: +977 9845733156;
Received date: March 04, 2021; Accepted date: March 23, 2021; Published date: April 27, 2021
Citation: Akhtar S. Current and Future Perspective of Glioblastoma, Molecular Heterogeneity with Clinical case. Neurol Neurosurg Curr Res. 2021;2(1):12-18.
Copyright: © 2021 Akhtar S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Glioblastoma multiforme is a highly vascular most common primary brain tumor which is extremely narcissistic in its character and function. It has high rates of recurrence despite neurosurgery, chemotherapy targeted therapy and radiotherapy. It is diligent endeavor of neurosurgeon and neurooncologist to make decision for patients who present with recurrence of this evil disease many times. This article is an attempt to delineate clinical spectrum molecular types character of this disease with a clinical experience of professionals dealing with this glioblastoma.
Methods: We have clinically examined patients in Neuro oncology department and Neurosurgery Department and provided best possible service to patients according to current evidence-based medicine. The modern guidelines have been followed in practice. We have been conducting meticulous discussion regarding glioblastoma and getting help from international experts for decision making and treatment planning of individual patients. A case was discussed by corresponding author in European School of Oncology live session.
Results: Majority of patients are returning back to Neuro physicians Neurosurgeons with recurrence of brain tumor with worsened health and debilitating morbidity.
Conclusion: Brain tumor scientific knowledge needs to be upgraded with biomarkers, new approach and newer drugs and surgical protocols.
Glioblastoma; Tumor heterogeneity; Molecular classification; Molecular heterogeneity; Primary brain tumor; Glioma.
OS: Overall Survival; PFS: Progression Free survival; EOR: Extent of Resection; IDH: Isocitrate dehydrogenase; ATRX: ATP-dependent X linked helicase; P53: A tumor protein; EGFR: Epidermal growth factor receptor; CCRT: concurrent chemo radiotherapy; MGMT: O -methylguanine-DNA methyltransferase; MRI: Magnetic Resonance Imaging; GBM: Glioblastoma multiforme